In March 2025, the Thai FDA published draft guidance introducing Unique Device Identifier (UDI) requirements for Class 2, 3, and 4 medical devices. A two-year transition period applies for devices already compliant with 2020 labeling rules. For foreign manufacturers supplying the Thai market, UDI compliance is a concrete technical and operational requirement that needs to be integrated into labeling, packaging, and supply chain systems within a defined and non-extendable timeline.
What UDI Requires
UDI has two components. The Device Identifier (DI) identifies the specific device model, version, and packaging configuration. The Production Identifier (PI) captures production-specific data including lot number, manufacture date, expiry date, and serial number where applicable. Both identifiers must be displayed on device labels in two forms: human-readable text, and a machine-readable AIDC carrier — either a linear barcode or a GS1 DataMatrix 2D code. The TFDA's UDI framework aligns with the IMDRF UDI guidance document, which was developed to enable international harmonization of UDI requirements across regulatory systems including the US FDA, EU MDR, and now Thailand.
The Transition Timeline
The March 2025 draft guidance introduced UDI requirements with a two-year transition period for devices already compliant with the 2020 labeling regulation. For new product registrations and registration renewals submitted during the transition period, UDI readiness is expected to be demonstrated as part of the application package. Manufacturers approaching renewal dates should not assume the transition period exempts their renewal submissions from UDI requirements. The practical consequence of inaction is a blocked renewal, not a deferred requirement. Manufacturers with renewals falling in 2026 and 2027 should be actively working on UDI assignment and labeling updates now.
UDI and the December 2025 Labeling Regulation
The UDI requirements sit alongside the broader labeling regulation B.E. 2568, published in the Royal Gazette on December 22, 2025, and effective June 20, 2026. That regulation updates Thai-language requirements, IFU content, and digital verification elements across all device categories. UDI implementation should be coordinated with the labeling B.E. 2568 compliance project so artwork revisions are done once rather than twice. Manufacturers who treat these as separate workstreams will incur unnecessary artwork revision costs.
Practical Compliance Steps
The implementation path involves four concrete steps. First, assign UDI codes through a TFDA-recognized issuing agency — GS1 is the most widely used globally and is recognized by the TFDA. Second, determine the correct DI and PI structure for each device type under IMDRF guidance and confirm TFDA-specific requirements. Third, update labeling and packaging artwork to include UDI elements in the required human-readable and AIDC format. Fourth, submit device and production identifier data to the TFDA UDI database — this is a standing operational requirement and not a one-time submission. DeeMED Consulting supports UDI implementation for foreign manufacturers supplying the Thai market, including GS1 registration guidance, TFDA database submissions, and label compliance review coordinated with the broader June 2026 labeling update.
Sources & Further Reading
- Asia Actual, "Thai FDA Drafts New Labeling Requirements for Medical Devices" — including March 2025 UDI draft guidance
- Pure Global, Thailand Medical Device Regulations — UDI transition period details
- IMDRF, IMDRF UDI Guidance Documents — international harmonization framework
- Complife Group, Regulation B.E. 2568 in Thailand: A Unified Framework for Medical Device Labeling
- Thai FDA, TFDA Medical Devices — regulatory framework